摘要
目的 探究心痛2号联合阿托伐他汀对经皮冠状动脉介入治疗(PCI)术后急性心肌梗死(AMI)患者心功能、血小板功能及术后再狭窄发生率的影响。方法 选择2020年4月至2022年1月唐山市中医医院收治的100例PCI术后AMI患者,采用随机数字表法将其分为对照组与研究组,每组50例。对照组采用常规干预+阿托伐他汀治疗,研究组采用常规干预+阿托伐他汀+心痛2号治疗。连续治疗6个月后,比较两组的临床疗效、心功能、血小板功能及术后再狭窄发生率。结果 研究组总有效率为90.00%(45/50),高于对照组74.00%(37/50)(χ^(2)=4.336,P=0.037)。治疗后,研究组患者左室射血分数[(61.24±7.99)%]、6 min步行试验距离[(423.77±52.57)m]均高于治疗前,且均高于对照组[(55.33±7.02)%、(391.52±49.11)m](t=3.929,3.171,均P<0.05)。治疗后,研究组和对照组左室收缩末内径[(21.27±3.05)、(29.33±4.24)mm]、室间隔厚度[(8.66±1.55)、(9.80±2.02)mm]、左室舒张末内径[(33.15±5.23)、(45.67±6.68)mm]、血小板聚集率[(22.66±5.02)%、(28.94±5.58)%]、血小板糖蛋白Ⅱb/Ⅲa[(16.13±3.47)、(21.85±4.84)]及血小板黏附率[(26.67±6.22)%、(30.84±6.88)%]均低于治疗前,两组比较差异均有统计学意义(t=10.912、3.166、10.435、5.916、6.792、3.179,均P<0.05)。对照组与研究组术后再狭窄发生率分别为16.00%(8/50)和4.00%(2/50),差异有统计学意义(χ^(2)=4.000,P=0.046)。结论 心痛2号联合阿托伐他汀治疗PCI术后AMI患者的疗效确切,能够改善患者心功能、血小板功能,降低术后再狭窄发生率。
Objective To explore the effect of Xintong No.2 combined with atorvastatin on cardiac function,platelet function,and restenosis rates of patients with acute myocardial infarction(AMI)following percutaneous coronary intervention(PCI).Methods A total of 100 patients undergoing PCI admitted to Tangshan Hospital of Traditional Chinese Medicine from April 2020 to January 2022 were enrolled in the study and divided into the control group and the study group using a random number table method,with 50 cases in each group.The control group was given conventional intervention plus atorvastatin,and the study group was treated with conventional intervention plus atorvastatin plus Xintong No.2.The clinical data of the patients was collected,and the clinical efficacy,cardiac function,platelet function and restenosis rates were compared between the two groups.Results The total effective rate of the study group was 90.00%(45/50),higher than 74.00%(37/50)of the control group(χ^(2)=4.336,P=0.037).After treatment,the left ventricular ejection fraction and 6-minute walk test distance of the study group were(61.24±7.99)%and(423.77±52.57)m,higher than(55.33±7.02)%and(391.52±49.11)m of the control group(t=3.929,3.171,both P<0.05),and the above indicators were higher than those before treatment.After treatment,the left ventricular end systolic diameter(LVESD)((21.27±3.05),(29.33±4.24)mm),left ventricular septal thickness(LVST)((8.66±1.55),(9.80±2.02)mm),left ventricular end diastolic diameter(LVEDD)((33.15±5.23),(45.67±6.68)mm),platelet aggregation rate(PAG)((22.66±5.02)%,(28.94±5.58)%),platelet membrane glycoprotein(GP)Ⅱb/Ⅲa((16.13±3.47),(21.85±4.84))and platelet adhesion rate(PAR)((26.67±6.22)%,(30.84±6.88)%)of the study group and the control group were lower than those before treatment,and the above indexes of the study group were lower than those of the control group(t=10.912,3.166,10.435,5.916,6.792,3.179,all P<0.05).The incidence of postoperative restenosis in the control group and the study group was 16.00%(8/50)and 4.00%(2/50),respectively,and the difference was statistically significant(χ^(2)=4.000,P=0.046).Conclusion Xintong No.2 combined with atorvastatin has a definite effect in the treatment of AMI patients after PCI.It can improve the cardiac function and platelet function,and reduce the incidence of postoperative restenosis.
作者
张晶
高蕴赫
高宪玺
ZHANG Jing;GAO Yunhe;GAO Xianxi(Department of Cardiology,Tangshan Hospital of Traditional Chinese Medicine,Tangshan 063000,China)
出处
《中国药物应用与监测》
2026年第1期131-134,共4页
Chinese Journal of Drug Application and Monitoring
基金
河北省中医药管理局科研计划项目(2021391)。
